BFC Planning’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$465 Buy
15
+1
+7% +$27 ﹤0.01% 3294
2026
Q2
$255 Sell
14
-1
-7% -$23 ﹤0.01% 3308
2026
Q1
$301 Hold
15
– – ﹤0.01% 2905
2025
Q4
$10K Hold
15
– – ﹤0.01% 2082
2025
Q3
$4.85K Buy
+15
New +$5K ﹤0.01% 2202
2025
Q2
– Sell
-15
Closed -$3.95K – 2808
2025
Q1
$3.95K Hold
15
– – ﹤0.01% 2102
2024
Q4
$5.56K Hold
15
– – ﹤0.01% 1982
2024
Q3
$2.31K Buy
+15
New +$2.15K ﹤0.01% 2250

Other funds holding IRLA

BFC Planning's IRLA Position: Q3 2026 in Review

BFC Planning increased its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 7.1% in Q3 2026, buying an estimated $27 and bringing the position to 15 shares worth $465. The position accounts for ﹤0.01% of the portfolio, ranked #3294.

BFC Planning first reported a position in IRLA in Q3 2024 and has held it in 8 quarters since. The position peaked at $10K in Q4 2025. 21 funds tracked by Wall St. Rank hold IRLA as of Q3 2026.

  • BFC Planning held 15 shares of IRulya Therapeutics Inc. Common Stock worth $465 as of Q3 2026.
  • BFC Planning bought 1 IRulya Therapeutics Inc. Common Stock share in Q3 2026, an estimated $27.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3294 holding.
  • BFC Planning first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2024 and has held it in 8 quarters since.
  • BFC Planning's IRulya Therapeutics Inc. Common Stock position peaked at $10K in Q4 2025.
  • 21 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.